VBLOC (vagal blocking for obesity control) device co files for IPO (initial public offering):
This article was originally published in Clinica
Executive Summary
EnteroMedics is looking to raise around $86m in an initial public offering of its common stock, the company said in a registration statement filed last week with the US Securities and Exchange Commission. The St Paul, Minnesota firm intends to use the proceeds to gain regulatory approval and initiate commercialisation of its VBLOC (vagal blocking for obesity control) therapy, which consists of using an electrostimulation implant to block the vagus nerves and control appetite.